Rimonabant, obesity and diabetes.
Too many adverse effects for a minor effect on weight loss, without reduced rates of complications.
D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects*
D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1